Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of New Oral Nicotine Spray in Healthy Japanese Smokers
NCT03398876Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2017
- Primary completion
- Apr 2018
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nicotine patch in Tobacco Use Disorder (TUD) (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Baseline Corrected Plasma Nicotine Concentration at 12 hours, Baseline Corrected Area Under the Plasma Nicotine Concentration vs Time Curve Until Last Measurable Time Point at 12 hours and 4 more. Started Dec 2017; status: completed.
02
Drugs
nicotine patch
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT03398876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03398876.